These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24303016)

  • 1. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST).
    Alaggio R; Turrini R; Boldrin D; Merlo A; Gambini C; Ferrari A; Dall'igna P; Coffin CM; Martines A; Bonaldi L; De Salvo GL; Zanovello P; Rosato A
    PLoS One; 2013; 8(11):e80456. PubMed ID: 24303016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.
    Kresse SH; Skårn M; Ohnstad HO; Namløs HM; Bjerkehagen B; Myklebost O; Meza-Zepeda LA
    Mol Cancer; 2008 Jun; 7():48. PubMed ID: 18522746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor.
    Krawczyk MA; Karpinsky G; Izycka-Swieszewska E; Gabrych A; Kunc M; Fatyga A; Garstka M; Styczewska M; Sokolewicz EM; Szlagatys-Sidorkiewicz A; Kazanowska B; Bien E
    Cancer Biomark; 2019; 24(3):351-361. PubMed ID: 30883338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP; Young ED; Belousov R; Zhang Y; Lopez G; Lusby K; Kivlin C; Demicco EG; Creighton CJ; Lazar AJ; Pollock RE; Lev D
    Clin Cancer Res; 2012 May; 18(9):2545-57. PubMed ID: 22407831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor.
    Karpinsky G; Krawczyk MA; Izycka-Swieszewska E; Fatyga A; Budka A; Balwierz W; Sobol G; Zalewska-Szewczyk B; Rychlowska-Pruszynska M; Klepacka T; Dembowska-Baginska B; Kazanowska B; Gabrych A; Bien E
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):519-529. PubMed ID: 29332262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours.
    Storlazzi CT; Brekke HR; Mandahl N; Brosjö O; Smeland S; Lothe RA; Mertens F
    J Pathol; 2006 Aug; 209(4):492-500. PubMed ID: 16721726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.
    Zou C; Smith KD; Liu J; Lahat G; Myers S; Wang WL; Zhang W; McCutcheon IE; Slopis JM; Lazar AJ; Pollock RE; Lev D
    Ann Surg; 2009 Jun; 249(6):1014-22. PubMed ID: 19474676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours.
    Karube K; Nabeshima K; Ishiguro M; Harada M; Iwasaki H
    J Clin Pathol; 2006 Feb; 59(2):160-5. PubMed ID: 16443732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
    Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
    J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST.
    Miao R; Wang H; Jacobson A; Lietz AP; Choy E; Raskin KA; Schwab JH; Deshpande V; Nielsen GP; DeLaney TF; Cote GM; Hornicek FJ; Chen YE
    Radiother Oncol; 2019 Aug; 137():61-70. PubMed ID: 31078939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection.
    Kolberg M; Høland M; Lind GE; Ågesen TH; Skotheim RI; Hall KS; Mandahl N; Smeland S; Mertens F; Davidson B; Lothe RA
    Mol Oncol; 2015 Jun; 9(6):1129-39. PubMed ID: 25769404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant peripheral nerve sheath tumors (MPNST): a SEER analysis of incidence across the age spectrum and therapeutic interventions in the pediatric population.
    Bates JE; Peterson CR; Dhakal S; Giampoli EJ; Constine LS
    Pediatr Blood Cancer; 2014 Nov; 61(11):1955-60. PubMed ID: 25130403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
    Holtkamp N; Atallah I; Okuducu AF; Mucha J; Hartmann C; Mautner VF; Friedrich RE; Mawrin C; von Deimling A
    Neoplasia; 2007 Aug; 9(8):671-7. PubMed ID: 17786186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant peripheral nerve sheath tumors in children, adolescents, and young adults: Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry.
    Meister MT; Scheer M; Hallmen E; Stegmaier S; Vokuhl C; von Kalle T; Fuchs J; Münter M; Niggli F; Ladenstein R; Kazanowska B; Ljungman G; Bielack S; Koscielniak E; Klingebiel T;
    J Surg Oncol; 2020 Dec; 122(7):1337-1347. PubMed ID: 32812260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of childhood malignant peripheral nerve sheath tumor.
    Ferrari A; Bisogno G; Carli M
    Paediatr Drugs; 2007; 9(4):239-48. PubMed ID: 17705563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation-based classification of benign and malignant peripheral nerve sheath tumors.
    Röhrich M; Koelsche C; Schrimpf D; Capper D; Sahm F; Kratz A; Reuss J; Hovestadt V; Jones DT; Bewerunge-Hudler M; Becker A; Weis J; Mawrin C; Mittelbronn M; Perry A; Mautner VF; Mechtersheimer G; Hartmann C; Okuducu AF; Arp M; Seiz-Rosenhagen M; Hänggi D; Heim S; Paulus W; Schittenhelm J; Ahmadi R; Herold-Mende C; Unterberg A; Pfister SM; von Deimling A; Reuss DE
    Acta Neuropathol; 2016 Jun; 131(6):877-87. PubMed ID: 26857854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors.
    Ikuta K; Urakawa H; Kozawa E; Arai E; Zhuo L; Futamura N; Hamada S; Kimata K; Ishiguro N; Nishida Y
    Clin Exp Metastasis; 2014 Aug; 31(6):715-25. PubMed ID: 24957185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Options for Malignant Peripheral Nerve Sheath Tumors.
    Hassan A; Pestana RC; Parkes A
    Curr Treat Options Oncol; 2021 Feb; 22(4):33. PubMed ID: 33641042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.